Lilly Humalog European Labeling Adds HbA1c Lowering Claim
Revised EU labeling for Lilly's Humalog (insulin lispro) includes a claim that the insulin analog reduces hemoglobin A1c more effectively than soluble insulin when administered in subcutaneous infusion pumps.
You may also be interested in...
Aventis will wait to launch the rapid-acting recombinant human insulin analog Apidra until after approval of the OptiClick pen delivery device
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011